INTRODUCTION
Major depressive disorder (MDD) is one of the most prevalent psychiatric disorders, leading to substantial suffering of the patients, a heavy burden for the family and significant socioeconomic consequences in terms of costs.
The study published by Moussavi et al. [1] reported data on the 12-month prevalence of MDD affects around 150 million adults worldwide and in Italy the number of people with this disease is estimated to be about 5 million, with a lifelong prevalence between 8 and 13% [3] . MDD is a commonly occurring, seriously impairing, and often recurring mental disorder [4] . In the last report, The World
Health Organization ranked MDD as the first leading cause of years lost due to disability worldwide and the third cause of disability worldwide projecting that by 2030 it will be the first leading cause [5] .
MDD constitutes an important burden both in terms of direct costs (e.g., treatments, hospitalizations) [6] , which represent 31% of the total costs, and also indirect costs (low productivity, comorbidities or death), which account for 62% of the overall costs of depression [7, 8] . Kind and Sorensen [9] showed that pharmacological treatments accounted for 11.3% of the total costs of MDD [10] . An estimation of the economic burden of MDD was $83.1 billion worldwide in 2004.
About 60% of patients affected by MDD never seek treatment or are undertreated [11] . MDD is associated with an increased risk of relapse after a first episode and a high risk of attempting suicide.
The main treatments used in MDD include antidepressant drugs, psychotherapy, and somatic treatment. Selective serotonin reuptake inhibitors (SSRIs) and serotoninnorepinephrine reuptake inhibitors (SNRIs) are two of the most effective classes of antidepressants with a higher safety profile than the tricyclic antidepressants (TCAs) [12] . SSRIs are also cost-effective in comparison with the older antidepressants in long-term treatment of MDD [12, 13] . Pharmacological antidepressant therapies remain the mainstay of treatment for MDD even if other interventions are also recommended [14, 15] .
There are many factors to consider when choosing an antidepressant: safety, tolerability, efficacy, etc., (Table 1) . SSRIs, SNRIs, and newer agents are nowadays considered first-line medications because they have better safety and tolerability profiles than the TCAs and monoamine oxidase (MAO) inhibitors [16] .
Even if a discussion regarding the efficacy of the different antidepressants is still open, many studies have demonstrated that this difference exists, not only in terms of efficacy but also in terms of tolerability and safety. A literature review by Cipriani et al. [17] Costs are now one of the most important factors to consider when choosing a therapy, not only with respect to the drug cost itself, but mostly for the other direct and indirect costs associated with the disease, and these represent a heavy burden, as previously mentioned.
Nevertheless, choosing a therapy taking into account only the costs and not outcome Fig. 1 .
MATERIALS AND METHODS

Description of the Model
The treatment objective was to achieve remission defined by a score of B7 on the Hamilton Depression Rating scale (HDRS). It was assumed that patients achieving remission in the initial treatment step of the model did it after 1 month of treatment [20] .
Once in remission, if patient relapses, it has been assumed that relapse occurs within 4 months since the start of treatment. If patient does not relapse (defined as a new MDD episode occurring within 6 months after remission) then she/he continued her/his treatment for 6 months (maintenance treatment) in accordance with the international guidelines.
Patients who do not respond move to a secondline treatment. A certain percentage of these patients could attempt suicide. Those patients who reach a remission state in second-line therapy, assumed to occur after 1 month, receive maintenance treatment for a further 6 months; instead, those patients who do not achieve remission in second-line therapy move to the third step. Patients move to third-and fourth-line therapy according to the same criteria described for second-line therapy.
Model Parameters
Efficacy An independent meta-analysis conducted by the TLV was used to retrieve remission probabilities for first-line treatment as detailed in Table 2 . Several studies were included in this meta-analysis with a total of about 20,000 patients [20] .
The expert panel considered this meta-analysis robust enough for the purpose of the present study because of the use of mixed treatment comparisons, a statistical method used to compare more than two treatments that were not part of the same direct head-to-head study.
Second-, third-, and fourth-line treatments as described in the Sequenced Treatment Alternatives to Relieve Depression Study (STAR*D) [22] , were analyzed and adapted to Italian standard clinical practice by the scientific expert panel ( Table 3 ).
The remission probabilities of these last treatment lines were discussed with the expert panel, which accorded to adapt STAR*D remission probabilities to the treatments that are not present in the reference study, but are the ones usually prescribed in the normal Italian clinical practice. For these treatments, remission probabilities were calculated using the mean remission probability of drug classes considered in the STAR*D study.
Regarding the probability of relapse, it was assumed that the risk of relapse was 11% and that relapse occurred within 4 months after remission [23] . Regarding suicide attempts and death probability, we considered the risk of (Table 5 ).
Local data from regional outpatient exams pricelists and hospitalization pricelists were used for resource utilization costs and for diagnosis and treatment costs based on the health service perspective of nine regions (Lombardia, Piemonte, Veneto, Toscana, Lazio, Campania, Sicilia, Puglia and Sardegna).
Population-based weighted regional data were used to feed the national model. All costs were expressed in Euros and updated to 2013 prices. Since an 1-year time horizon had been set, no discounting was applied. Medication costs were obtained from SSRIs selective serotonin reuptake inhibitors, SNRIs serotonin-norepinephrine reuptake inhibitors, NDRI norepinephrine-dopamine reuptake inhibitor, NRI norepinephrine reuptake inhibitor, NASSA noradrenergic and specific serotonergic antidepressant, I-MAO monoamine oxidase inhibitors Table 5 .
For generic drugs, we considered the prices that are reimbursed by the health service, whereas for the branded drugs we considered the public prices. In both cases, a co-payment (ticket) was subtracted from the respective prices for each drug prescription directly paid by the patient.
Regarding drug doses, we used the DDD retrieved from the website of the WHO
Collaborative Center for Drug Statistics
Methodology which, as assessed by the expert panel, fit well with Italian normal clinical practice [27] . A scenario analysis was performed using the MD derived from the SPC. Utility values have been derived from Sobocki et al. [28] , where a patient who achieves remission and a patient who does not have a utility of 0.81 and 0.57, respectively. TLV model assumed that the utility for patients who attempt suicide and the utility for patients in relapse were equal to those of the patients who do not achieve remission. The expert panel did [21] . Nevertheless, in this study we will talk generally about CEA.
The principal outcomes of CEA are mean costs and QALYs for all treatment strategies and the incremental cost-effectiveness ratios (ICERs), which are the observed differences in costs divided by differences in outcomes between two alternative programs. The ICER should be interpreted as the additional cost required to gain an additional unit of health outcome (QALY) when providing one treatment rather than another one. In this study, due to the lack of official willingness to pay threshold in Italy, we decided to use an ICER threshold of € 25,000 per QALY, slightly lower than the one recognized by the National Institute for Health and Clinical Excellence (NICE).
The interpretation of CEA results depends on the level of confidence or uncertainty of the parameters considered in the model. It is crucial to understand the impact of using alternative parameter values and examining the sensitivity of the model when changing its inputs. The authors have assumed to perform the following scenario analyses:
• Mean dose calculated from the min and max dose ranges calculated from the SPC
• Utility values derived from Sobocki et al. [28] .
Furthermore, a one-way sensitivity analyses was performed on the remission probability, as this is the most crucial drug-specific parameter of the model, to test how changes in this parameter will impact on the results.
Another way to test the uncertainty is the probabilistic sensitivity analysis (PSA) using Monte Carlo simulations. In the PSA, the uncertainty around single input parameter values is characterized by probability distributions. Gamma distributions were used for costs, except for treatments costs in which we applied deterministic costs, while Beta distributions were applied for all the probabilities and all the utilities of the model.
In the PSA, the uncertainty in all model inputs is evaluated simultaneously using simulation techniques. In the simulation involving parameters, values are drawn randomly from the probability functions generating mean costs and mean effects for Adapted from: ref. [28] each strategy. This procedure was repeated 10,000 times, generating 10,000 estimates of mean costs and mean effects. The results of the probabilistic analysis were summarized as the probability of each treatment strategy being cost-effective at different willingness-to-pay values using costeffectiveness acceptability curves (CEAC).
RESULTS
Base-case Analysis
The results of the CEA are shown in Table 7 .
Despite its relatively high acquisition cost, the 
Alternative Scenarios and One-Way Sensitivity Analyses
Two alternative scenarios were tested: the first was the use of mean dose for calculating drug costs instead of the defined daily dosages used in the base-case scenario. Results shown in Table 8 (Table 9 ).
With escitalopram being the dominant drug, a one-way sensitivity analysis was performed on its remission probability to evaluate a possible loss of dominance. By reducing the remission probability of escitalopram by 5%, escitalopram lost the dominance in comparison with (Table 10) . 
ICER incremental cost-effectiveness ratio
Probabilistic Sensitivity Analyses
The cost-effectiveness acceptability curves are presented in Fig. 3 . For every threshold of willingness to pay, escitalopram was the most cost-effective antidepressant. Given a maximum acceptable ratio (threshold) of € 25,000 per QALY gained, the probability that escitalopram is cost-effective compared with the other treatments is 0.34. This is equivalent to stating that there is a 34% chance that the additional cost of escitalopram therapy, compared with the other treatments, is \€ 25,000 per QALY gained. Furthermore, compared with the other treatments, there is a 26% of probability that escitalopram is costeffective at a willingness to pay equal to zero, meaning that it is dominant in comparison with the other treatments. Another similarity with the model presented in this paper is that it was also based on the TLV setting, could be a potential limitation, although the probabilities of clinical events are not usually considered to be country-specific [31] . A limitation on the model assumptions could be the time (1 month) used for evaluating remission. In the STAR*D study [22] it took on average approximately 6 weeks to remission so authors' approach could be considered an underestimation. Nevertheless, the expert panel agreed to apply 1 month to reach remission as proposed in the TLV model [20] . Another limitation of this study is due to the lack of local data regarding treatment patterns, resource utilization, and some utilities, information that the authors based on estimates from the expert panel. Nevertheless, using expert opinion could be considered appropriate when there is little or no published material, or when the findings from a literature review are considered conflicting, unreliable, or insufficient to cover the study requirements [33] . Another process that could be considered as a potential limitation is represented by the estimated national costs based on means costs weighted by the population of nine regions.
DISCUSSION
Nevertheless, because the Italian healthcare system decentralizes the administrative decisions at regional level by creating several pricelists for each region, the only way to retrieve a national cost data was applying a weighted mean to the regional data.
CONCLUSIONS
The results from this cost-effectiveness analysis indicate that escitalopram is the most costeffective pharmacological treatment strategy for the Italian health service compared with all SSRIs and all SNRIs used in the first-line treatment of major depressive disorder.
Although escitalopram has a relatively high acquisition cost, it is associated with a lower total cost compared with all other treatment strategies and with a larger health gain (QALYs) over a 1-year time horizon, dominating the other treatment strategies when assessing costeffectiveness of antidepressants. Prof. Mencacci is the guarantor of the study and takes responsibility for the integrity of the work as a whole. This study and the article processing charges were financially supported by an unrestricted grant from Lundbeck Italy SpA, which was not responsible for creation of the study documents, the data analysis, data interpretation, or writing of the manuscript.
